The Vaccine Damage Payments Act (Review) Bill requires the Secretary of State to review whether the statutory lump-sum payment under the Vaccine Damage Payments Act 1979 should be increased for all claims from 1 January 2020 by an amount equal to the cumulative rise in consumer prices since 2007. The Bill directs the Secretary to use the Statistics Board’s general index for consumer prices when assessing the inflation adjustment, to consult claimants and named advocacy and patient-safety groups, and to publish a report and lay it before Parliament within six months of the Act’s passage.
This is a report-and-review measure, not an automatic uprating: the Bill creates a duty to examine and publish findings, not to change payment law or make payments. For professionals, the Bill triggers a short, formal review process with a named calculation method and a fixed publication deadline; if ministers act on the report, it could create a discrete fiscal and administrative exercise and raise questions about retrospective fairness and devolved responsibilities for health policy implementation.
At a Glance
What It Does
The Bill imposes a statutory duty on the Secretary of State to review the merits of increasing the Vaccine Damage Payments Act 1979 lump sum for claims from 1 January 2020 by the cumulative increase in consumer prices since 2007, using the Statistics Board’s general index for consumer prices. It requires consultations with claimants, representatives, UKCVFamily and patient-safety groups and mandates a report to be published and laid before Parliament within six months of enactment.
Who It Affects
Directly affects people who have made vaccine damage claims since 1 January 2020 and their advisers, advocacy groups such as UKCVFamily and patient-safety organisations that will be consulted, and the Department of Health and Social Care and the Treasury, which would need to cost and potentially implement any recommended changes. Devolved administrations will have an interest because health policy and service delivery are largely devolved.
Why It Matters
The statutory payment set under the 1979 Act has not tracked long-term inflation; this Bill forces a short, administratively bounded assessment using a named price index and a defined base year. That technical framing narrows the scope of debate to index choice, scope of retrospective application and fiscal impact—issues that matter to claimants, legal advisers, and officials calculating potential liabilities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Bill creates a single, limited task: the Secretary of State must examine whether the lump-sum payment available under the Vaccine Damage Payments Act 1979 should be increased for all claims made since 1 January 2020 by an amount that reflects how much consumer prices have risen since 2007. It defines how the Secretary should approach the arithmetic by saying the general index for consumer prices published by the Statistics Board should be used as the reference point for calculating that inflationary amount.
The Bill stops short of any automatic uplift—its legal effect is to require a review and a public report, not to alter the statutory payment or to order payments to be made.
The Bill also prescribes who must be consulted during the review: people who made claims and their families, organisations representing those claimants, UKCVFamily, patient-safety groups, and any other parties the Secretary considers relevant. That list channels the evidentiary input toward claimant perspectives and safety advocates; it does not, however, prescribe consultation with devolved health departments, ministers of finance, or wider economic stakeholders.
Importantly, the Secretary has a tight timetable: the report must be published and laid before Parliament within six months of the Act becoming law.Practically, an effective report will need to translate an index figure into policy options: whether to make a one-off retrospective payment to eligible claimants, to uprate the statutory sum going forward, or to recommend a different mechanism (for example, linkage to future indexation). Officials will need to estimate the number of qualifying claims, the likely aggregate cost of any uprating, and the administrative steps required to make retrospective payments.
Because the Bill applies UK‑wide, it also raises coordination questions with Scotland, Wales and Northern Ireland about implementation and budget responsibility should ministers choose to act on their own findings.
The Five Things You Need to Know
The Bill requires a review specifically of uprating the ‘relevant statutory sum’ for Vaccine Damage Payments for all claims since 1 January 2020.
When assessing the inflation increase, the Secretary of State must have regard to the general index for consumer prices published by the Statistics Board (i.e.
CPI as maintained by the national statistics authority).
The Bill mandates consultation with people who have made claims and their families, representative organisations, UKCVFamily, patient-safety groups, and other persons the Secretary considers relevant.
The Secretary of State must publish and lay a report of the review before Parliament within six months of the Act’s passage.
The Act extends to England and Wales, Scotland and Northern Ireland and comes into force on the day it is passed; it creates a reporting duty but does not itself change payment levels or create entitlement to increased sums.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Duty to review uprating for 2020-onwards claims
This subsection creates the central statutory obligation: the Secretary of State must carry out a review into the merits of increasing the payment available under the Vaccine Damage Payments Act 1979 for claims from 1 January 2020. The practical effect is to force officials to frame the policy question, gather data on eligible claims, and present a policy and fiscal assessment to ministers and Parliament.
Indexation method required: general index for consumer prices
The Bill directs that the calculation of the inflationary increase should have regard to the general index for consumer prices published by the Statistics Board. That instruction narrows methodological debate to a single official index and a single measuring body, which limits the range of technical arguments (for example RPI vs CPI) in the review—although it does not preclude discussion of alternatives in the report itself.
Consultation list and publication deadline
Subsections (3) and (4) set out a short, specific consultation list—claimants and families, representative organisations, UKCVFamily and patient-safety groups—and require publication and laying of the review report within six months of enactment. The combined effect is a compressed timetable with a claimant-focused evidence base and limited mandatory stakeholder parties, placing practical pressure on officials to organise outreach and to produce cost estimates swiftly.
Definitions, territorial extent and commencement
Subsection (5) ties the phrase ‘relevant statutory sum’ back to section 1 of the 1979 Act, ensuring the review targets the statutory lump sum rather than related benefits or payments. Section 2 confirms the Bill’s UK-wide extent (England and Wales, Scotland and Northern Ireland), immediate commencement on passage, and short title. The territorial reach signals that any policy change would be UK-wide, even though health policy is largely devolved, which raises implementation and funding coordination questions if ministers act on the review.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People who made Vaccine Damage Payments claims on or after 1 January 2020 — they gain a formal government review that could lead to higher lump‑sum awards or retrospective top‑ups.
- Claimants’ families and legal advisers — the review provides official recognition of inflation erosion and could create work and fee opportunities for advisers if the government decides on retrospective payments.
- UKCVFamily and patient-safety groups — named consultees obtain a guaranteed platform to present evidence and policy arguments directly into the official review.
- Parliamentarians and oversight bodies — they receive an authoritative report within a fixed timeframe to inform scrutiny, inquiries, or follow-up legislation.
Who Bears the Cost
- HM Treasury / the Exchequer — if the review leads to a recommendation and ministerial decision to increase payments, the fiscal cost of uprating and any retrospective payments would fall on public spending.
- Department of Health and Social Care (DHSC) and implementing agencies — officials must organize the review, consult, estimate liabilities, and, if directed, design and deliver any adjustment mechanism, absorbing administrative costs and staff time.
- Small charities and patient groups — mandated consultations require time and resources to prepare submissions and may divert scarce capacity toward the review process.
- Devolved administrations — although the Bill extends UK‑wide, implementation choices could impose coordination, reporting or funding implications on Scotland, Wales and Northern Ireland where health delivery is devolved.
Key Issues
The Core Tension
The central tension is between correcting an accumulation of lost value in a decades‑old, fixed lump-sum payment—arguing moral and fairness grounds for updating compensation—and the fiscal, legal and precedent risks of retroactive uprating: choosing an index and base year, limiting scope to a subset of claimants, and committing public funds or requiring fresh primary legislation. The Bill forces a choice between targeted recognition for a specific cohort and the broader implications for compensation architecture and public budgets.
The Bill is narrowly framed but raises several practical and policy trade-offs. First, specifying the Statistics Board’s general consumer price index and a 2007 base year fixes the arithmetic in a way that materially affects cost estimates: choice of index and base year can move totals by millions.
The Bill does not explain why 2007 is the reference point, nor does it address whether compound cumulative inflation or another uprating method should apply. Officials preparing the review must therefore justify the technical approach they use and explain any deviations.
Second, the Bill covers claims from 1 January 2020 only. That creates an equity and precedent problem: claimants with older or later dates could argue for parity, and ministers will need to decide whether to confine remedial action to this cohort or to recommend a broader change.
Moreover, the Bill requires only a report; changing the statutory sum will likely need primary legislation and budget allocation. That means the review could produce a high-profile report with no immediate relief, creating political and practical pressure without automatically delivering payments.
Finally, because health is devolved, a UK-wide recommendation would require coordinated implementation and clear funding lines if ministers choose to act.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.